微型RNA市場－全球產業規模、佔有率、趨勢、機會及預測（按產品/服務、應用、最終用戶、地區和競爭對手分類），2021-2031年

全球微型RNA市場預計將從2025年的17.2億美元成長到2031年的32.4億美元，複合年成長率為11.13%。

微型RNA）作為小型非編碼RNA分子，透過抑制翻譯或標靶分解傳訊RNA）在基因表現調控中發揮至關重要的作用。該市場的成長主要受慢性病發病率上升以及精準生物標記在早期診斷中的重要性所驅動。基因組技術融入臨床工作流程以實現精準的疾病分析，進一步推動了這一趨勢。美國癌症協會預測，到2024年美國將新增2,001,140例癌症病例，凸顯了微型RNA分析所提供的先進診斷能力的重要性，也說明了該領域的迫切性。

市場成長的主要障礙在於缺乏標準化的通訊協定製備和檢測方案。 RNA天然的不穩定性，加上不同檢測平台之間的技術差異，常導致數據重複性問題。這種不一致使得廣泛臨床應用所需的監管檢驗流程變得複雜，從而對市場擴張構成重大阻礙。

市場促進因素

全球癌症和慢性疾病的日益普及是推動全球微型RNA市場發展的主要動力，也微型RNA產生了對能夠早期檢測和疾病管理的先進診斷工具的強勁需求。 microRNA因其在生物體液中的穩定性以及在病理條件下特異性表達模式而備受重視，使其成為液態生物檢體應用的理想候選者。惡性腫瘤負擔的不斷加重進一步加劇了這種需求。例如，世界衛生組織（WHO）在2024年2月報告稱，肺癌將成為全球最常見的癌症，預計新增病例將達250萬例左右。如此高的發生率迫切需要採用微型RNA譜分析來解析複雜的疾病機制，以實現及時有效的治療性介入。

同時，加速推進的臨床開發和策略聯盟正在驗證基於微型RNA治療方法的療效，重塑市場格局。製藥公司正積極投資前景廣闊的資產，透過收購和合作拓展其在心血管和代謝疾病領域的產品組合。這一趨勢的一個顯著例證是，諾和諾德在2024年3月達成協議，將以高達10.25億歐元的價格收購Cardiol Pharmaceuticals，以獲得一種用於治療心臟衰竭的領先RNA標靶化合物。這一財務動能與臨床進展相輔相成。 2024年3月，Regulus Therapeutics公佈了其RGLS8429 1b期研究的積極頂線數據，顯示腎臟疾病生物標記顯著改善，並標誌著市場正朝著商業性可行的治療方案邁進。

市場挑戰

全球微型RNA市場面臨的主要障礙之一是樣本製備和檢測通訊協定缺乏標準化。由於RNA本身的不穩定性，即使分離和處理技術上的微小差異也會導致不同實驗室間數據出現顯著差異。這種技術上的不一致造成了信任度的缺失，一項研究中發現的生物標記譜往往無法在後續研究中重複驗證。由此導致的無法產生可重複數據，使得監管機構要求的檢驗流程複雜化，並延緩了基於微型RNA的新型診斷工具的核准和商業化進程。

這種差異性對臨床工作流程有重大影響，因為不一致的檢測方法無法可靠地擴展到廣泛的臨床應用，直接抑制了市場信心和應用。產業對檢查室準確性的分析從數量上凸顯了這個問題的嚴重性：根據美國臨床實驗室醫學學會 (ASCL) 的數據，到 2024 年，檢測前誤差將佔所有檢測誤差的約 43% 至 75%。基礎檢測階段如此高的錯誤率凸顯了監管機構為何對核准微型RNA診斷保持謹慎，最終抑制了該領域的收入成長。

市場趨勢

將人工智慧 (AI) 應用於微型RNA模式分析正在革新該領域，克服了以往阻礙生物標記發現的複雜結構預測難題。先進的深度學習模型現在能夠精確模擬 RNA 分子與細胞標靶之間複雜的3D相互作用，從而加速有效候選療法的識別。 Google DeepMind 於 2024 年 5 月發布了 AlphaFold 3，這是該領域的一項重大突破。 AlphaFold 3 預測蛋白質-DNA-RNA 交互作用的準確率比現有方法高出至少 50%。運算能力的飛躍將使研究人員能夠更有效地繪製微型RNA調控網路，顯著縮短早期標靶檢驗所需的時間。

同時，脂質奈米顆粒 (LNP) 和 GalNAc（N-乙醯葡萄糖胺）遞送系統的創新正在解決將 RNA 有效載荷遞送至肝臟以外組織的關鍵挑戰。雖然傳統載體主要局限於肝臟蓄積，但新一代平台正被設計成具有選擇性器官標靶化能力，能夠到達肺和脾臟等器官。這項技術進步正得到定向投資的積極支持。例如，據 ReCode Therapeutics 公司稱，囊腫纖維化基金會於 2024 年 11 月同意投資高達 1500 萬美元，以支持該公司開發用於肺細胞基因修復的組織特異性脂質奈米顆粒。此類遞送結構的進步對於將微型RNA療法的臨床效用從代謝性疾病擴展到呼吸系統和全身性疾病至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球微型RNA市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品/服務分類（產品、消耗品、服務）
  • 依應用領域（癌症、感染疾病、免疫系統疾病、心血管疾病、神經系統疾病等）
  • 依最終用戶分類（生物技術/製藥公司、學術/政府研究機構、其他最終用戶）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美微型RNA市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲微型RNA市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區微型RNA市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲微型RNA市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲微型RNA市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球微型RNA市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific, Inc.
• Horizon Discovery Ltd.
• OriGene Technologies, Inc.
• QIAGEN
• GeneCopoeia, Inc.
• Merck KGaA
• Miltenyi Biotec
• Sistemic Scotland Limited
• SeqMatic LLC
• Biodynamics Laboratory Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global MicroRNA market is projected to expand from USD 1.72 Billion in 2025 to USD 3.24 Billion by 2031, reflecting a compound annual growth rate of 11.13%. Functioning as small non-coding RNA molecules, microRNAs are essential for regulating gene expression by either suppressing translation or targeting messenger RNA for degradation. The market is primarily propelled by the rising incidence of chronic diseases and the critical need for precise biomarkers to facilitate early diagnosis, a trend further supported by the incorporation of genomic technologies into clinical workflows for accurate disease profiling. Highlighting the urgency driving this sector, the American Cancer Society projected that 2,001,140 new cancer cases would occur in the United States in 2024, emphasizing the vital necessity for the advanced diagnostic capabilities offered by microRNA analysis.

A major obstacle hindering market growth is the absence of standardized protocols for sample preparation and detection. The natural instability of RNA, coupled with technical variations across different assay platforms, frequently results in issues with data reproducibility. This inconsistency complicates the regulatory validation processes required for widespread clinical adoption, creating significant barriers to market expansion.

Market Driver

The increasing global prevalence of cancer and chronic diseases acts as a primary engine for the Global MicroRNA market, creating a strong demand for advanced diagnostic tools capable of early detection and disease management. MicroRNAs are increasingly valued for their stability in biofluids and their specific expression patterns during pathological states, making them excellent candidates for liquid biopsy applications. This need is amplified by the growing burden of malignancies; for instance, the World Health Organization reported in February 2024 that lung cancer remained the most common cancer globally, with approximately 2.5 million new cases. Such high incidence rates necessitate the urgent adoption of microRNA profiling to decode complex disease mechanisms and enable timely therapeutic interventions.

Simultaneously, the market landscape is being reshaped by accelerating clinical development and strategic partnerships that validate microRNA-based therapeutic modalities. Pharmaceutical companies are actively investing in promising assets to broaden their cardiovascular and metabolic portfolios through acquisitions and collaborative agreements. A prominent example of this trend involves Novo Nordisk, which agreed in March 2024 to acquire Cardior Pharmaceuticals for up to 1.025 billion Euros to secure a leading RNA-targeting compound for heart failure. This financial momentum is matched by clinical progress, as evidenced by Regulus Therapeutics in March 2024, when positive topline data from its Phase 1b trial for RGLS8429 showed distinct improvements in kidney disease biomarkers, signaling the market's progression toward commercially viable therapeutic solutions.

Market Challenge

The principal barrier restricting the Global MicroRNA market is the critical lack of standardization in sample preparation and detection protocols. Due to the inherent instability of RNA, even slight deviations in isolation or handling techniques can lead to substantial data discrepancies between laboratories. This technical inconsistency creates a reliability gap, where biomarker profiles identified in one study often fail to replicate in subsequent research. Consequently, the inability to produce reproducible data complicates the validation process required by regulatory bodies, thereby delaying the approval and commercialization of new microRNA-based diagnostic tools.

This variability has a significant impact on clinical workflows, as assays lacking uniformity cannot be reliably scaled for widespread medical use, which directly suppresses market confidence and adoption rates. The severity of this issue is quantitatively highlighted by industry analysis regarding laboratory precision; according to the Association for Diagnostics & Laboratory Medicine, in 2024, preanalytical errors were responsible for approximately 43% to 75% of all laboratory errors. Such high error rates in the foundational stages of testing underscore why regulatory agencies remain hesitant to approve microRNA diagnostics, ultimately stalling the sector's revenue growth.

Market Trends

The sector is undergoing a fundamental shift due to the integration of Artificial Intelligence for microRNA pattern analysis, which is resolving complex structural prediction challenges that previously hindered biomarker discovery. Advanced deep learning models are now capable of modeling the intricate three-dimensional interactions between RNA molecules and cellular targets with high precision, thereby accelerating the identification of viable therapeutic candidates. A major advancement in this domain was established when, according to Google DeepMind, in May 2024, the company released AlphaFold 3, which predicts the interactions of proteins with DNA and RNA with at least a 50% improvement in accuracy compared to existing methods. This leap in computational capability allows researchers to map microRNA regulatory networks more effectively, significantly reducing the time required for early-stage target validation.

Simultaneously, innovation in Lipid Nanoparticle and GalNAc delivery systems is addressing the critical bottleneck of delivering RNA payloads to extra-hepatic tissues. While earlier carriers were predominantly limited to liver accumulation, next-generation platforms are being engineered with selective organ targeting capabilities to reach organs such as the lungs and spleen. This technical evolution is actively supported by targeted investments; for instance, according to ReCode Therapeutics, in November 2024, the Cystic Fibrosis Foundation agreed to invest up to $15 million to support the company's development of tissue-specific lipid nanoparticles for gene correction in lung cells. Such advancements in delivery architecture are essential for expanding the clinical utility of microRNA therapeutics beyond metabolic disorders into respiratory and systemic conditions.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Horizon Discovery Ltd.
• OriGene Technologies, Inc.
• QIAGEN
• GeneCopoeia, Inc.
• Merck KGaA
• Miltenyi Biotec
• Sistemic Scotland Limited
• SeqMatic LLC
• Biodynamics Laboratory Inc.

Report Scope

In this report, the Global MicroRNA market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

MicroRNA market, By Product & Service

• Products
• Consumables
• Services

MicroRNA market, By Application

• Cancer
• Infectious Diseases
• Immunological Disorder
• Cardiovascular Disease
• Neurological Disease
• Others

MicroRNA market, By End User

• Biotechnology & Pharmaceutical Companies
• Academic & Government Research Institutes
• Other end users

MicroRNA market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MicroRNA market.

Available Customizations:

Global MicroRNA market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global MicroRNA market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (Products, Consumables, Services)
  • 5.2.2. By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others)
  • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Other end users)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America MicroRNA market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States MicroRNA market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada MicroRNA market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico MicroRNA market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe MicroRNA market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany MicroRNA market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France MicroRNA market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom MicroRNA market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy MicroRNA market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain MicroRNA market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific MicroRNA market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China MicroRNA market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India MicroRNA market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan MicroRNA market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea MicroRNA market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia MicroRNA market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa MicroRNA market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia MicroRNA market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE MicroRNA market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa MicroRNA market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America MicroRNA market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil MicroRNA market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia MicroRNA market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina MicroRNA market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global MicroRNA market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Horizon Discovery Ltd.
• 15.3. OriGene Technologies, Inc.
• 15.4. QIAGEN
• 15.5. GeneCopoeia, Inc.
• 15.6. Merck KGaA
• 15.7. Miltenyi Biotec
• 15.8. Sistemic Scotland Limited
• 15.9. SeqMatic LLC
• 15.10. Biodynamics Laboratory Inc.

16. Strategic Recommendations

17. About Us & Disclaimer